Mometasone Teva (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the nasal mucosa, altering gene expression to suppress inflammatory cytokines, reduce vascular permeability, and limit leukocyte infiltration. This anti‑inflammatory action decreases swelling and irritation of the nasal passages.

The specific dose and frequency of Mometasone Teva are determined by the prescribing clinician based on the patient’s age, severity of symptoms, and therapeutic response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mometasone furoate in pregnancy and lactation are limited. Healthcare providers usually weigh potential benefits against risks before prescribing. Women who are pregnant, planning pregnancy, or breastfeeding should discuss their situation with a qualified medical professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with a favorable safety profile when used as directed. Compared with agents such as fluticasone or budesonide, mometasone often requires fewer daily sprays to achieve similar symptom control, but individual response may vary.

Store the nasal spray at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and discard any product that appears discolored or has an altered odor.

Mometasone Teva is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of actuations while breathing in gently. The process is repeated in the other nostril if directed.

Serious risks, though rare, include nasal septal perforation, severe allergic reactions (anaphylaxis), adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal cavity. Patients should seek immediate medical attention if they experience unusual bleeding, vision changes, or signs of systemic corticosteroid effects.

Mometasone Teva should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation, and in patients with untreated bacterial, viral, or fungal nasal infections. Caution is also advised for patients with glaucoma, cataracts, or a history of adrenal insufficiency.